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ARTICLE
Is there an effect of intranasal insulin on development
and behaviour in Phelan-McDermid syndrome? A
randomized, double-blind, placebo-controlled trial
Renée J Zwanenburg1, Gianni Bocca2, Selma AJ Ruiter3, Jan H Dillingh4, Boudien CT Flapper2,
Edwin R van den Heuvel5 and Conny MA van Ravenswaaij-Arts*,1
Phelan-McDermid syndrome (PMS) or 22q13.3 deletion syndrome is a rare neurodevelopmental disorder with at least 60
children and 35 adults diagnosed in the Netherlands. Clinical features are moderate to severe intellectual disability and
behavioural problems in the autism spectrum. Other researchers had observed a beneﬁcial effect of intranasal insulin on
development and behaviour in a pilot study in six children with PMS. To validate this effect, we conducted a randomized,
double-blind, placebo-controlled clinical trial using a stepped-wedge design. From March 2013 to June 2015, 25 children aged
1–16 years with a molecularly conﬁrmed 22q13.3 deletion including the SHANK3 gene participated in the clinical trial for a
period of 18 months. Starting 6 months before the trial, children were systematically assessed for cognitive, language and motor
development and for adaptive, social and emotional behaviour every 6 months. The second, third and fourth assessments were
followed by daily nose sprays containing either intranasal insulin or intranasal placebo for a 6-month period. A ﬁfth assessment
was done directly after the end of the trial. Intranasal insulin did not cause serious adverse events. It increased the level of
developmental functioning by 0.4–1.4 months per 6-month period, but the effect was not statistically signiﬁcant in this small
group. We found a stronger effect of intranasal insulin, being signiﬁcant for cognition and social skills, for children older than 3
years, who usually show a decrease of developmental growth. However, clinical trials in larger study populations are required to
prove the therapeutic effect of intranasal insulin in PMS.
European Journal of Human Genetics advance online publication, 31 August 2016; doi:10.1038/ejhg.2016.109
INTRODUCTION
Phelan-McDermid syndrome (PMS, OMIM 606232) is caused by a
deletion on chromosome 22q13.3 that results in a neurodevelopmental
disorder. There are at least 60 children and 35 adults diagnosed with
this syndrome in the Netherlands. The main clinical features of PMS
are intellectual disability and behavioural problems in the autism
spectrum.1 The behavioural proﬁle is characterised by a general delay
in adaptive behaviour, which is seen as deﬁcits in social
communication.2 In a recent study, we showed less favourable
developmental growth in PMS patients after the age of 3 years, with
a slow but steady increase in developmental abilities up to that age that
is followed by decreased or stagnated developmental growth after.3
The neurodevelopmental features in PMS are mainly caused by a
deletion of the SHANK3 gene (OMIM 606230).4 Mutations in this
gene have been reported in humans with intellectual disability and
with autism (reviewed by Leblond et al.),5 and have been shown to
cause deﬁcits in social interaction and learning in animal models.6,7
SHANK3 is a scaffold protein located at axon terminals and
postsynaptic densities of neurons that has an important role in
synaptic maturation and neuronal signalling.8,9 Neurons derived from
induced pluripotent stem cells of PMS patients showed reduced
SHANK3 mRNA and protein expression, a decreased number of
excitatory neurotransmitter-receptors and fewer excitatory synapses.9
As the molecular mechanisms underlying the syndrome are uncov-
ered, research is gradually focusing on developing therapeutic strate-
gies at the biological level. One strategy is the administration of
insulin-like growth factor 1 (IGF-1), which has been reported to
reverse deﬁcits in synaptic signalling in heterozygous Shank3-deﬁcient
mice.10 In a randomized placebo-controlled crossover pilot study, nine
children with PMS were treated with daily intraperitoneal IGF-1
injections over a period of 12 weeks. The results showed an
improvement of social impairment and restrictive behaviour.11 A
non-invasive therapeutic strategy is treatment with intranasally admi-
nistered insulin. Intranasal application leads to uptake of insulin in the
cerebral spinal ﬂuid (CSF), bypassing the blood–brain barrier.12
Insulin administered by this route has been shown to improve
memory, general cognition, functional abilities and mood in healthy
adults, adults with Alzheimer’s disease and adults with minimal
cognitive impairment without causing systemic effects on blood
glucose levels or other serious adverse events (SAEs; reviewed by
Shemesh et al.).13,14 Schmidt et al. hypothesised that intranasal insulin
could compensate for the cognitive deﬁcits in PMS and conducted an
exploratory non-placebo-controlled study in six children with PMS.15
They reported an improvement of motor activity, cognitive function,
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nonverbal communication and autonomy after treatment with intra-
nasal insulin, without an effect on blood glucose levels or SAEs.
However, replication of these effects in a clinical trial with a larger
number of participants is needed.
The aim of our study was to evaluate the effect of intranasal insulin
on development and behaviour in a larger group of children with PMS
using a randomized, double-blind, placebo-controlled clinical trial.
SUBJECTS AND METHODS
Study design and subjects
The study is a monocenter, randomized, double-blind, placebo-controlled trial
with a stepped wedge design including three study groups.16 Before the clinical
trial, we statistically evaluated several different trial designs (parallel group
design, matched-pairs design, wait-list design and stepped wedge design) and
found the stepped wedge design showed the highest power for testing treatment
effect.16 The stepped wedge design is especially appropriate for studies in which
the intervention is expected to do more good than harm, a situation in which it
is considered unethical to withhold treatment from a subgroup of participants
(as in parallel group design) or to only provide treatment to all participants if
the effect has been proven to be effective (as in wait-list design). With the
stepped wedge design, the change from intranasal placebo to intranasal insulin
occurs at different time points for each study group (Figure 1).
The study was performed between March 2013 and June 2015. Patients were
recruited from a group of 38 Dutch children with PMS who had been
diagnosed in the Clinical Genetics department of the University Medical Centre
Groningen or referred to our centre from other hospitals in the Netherlands.
Inclusion criteria were a molecularly conﬁrmed 22q13.3 deletion including
SHANK3, a calendar age between 12 months and 18 years, and having parents
who understand and speak Dutch (necessary because of the nature of the
assessments). Children with severe (perinatal) brain damage or with a
metabolic or neuromuscular disease were excluded because development and
behaviour could be signiﬁcantly inﬂuenced by these factors and less dependent
on their SHANK3 deﬁciency, the hypothetical target of the treatment. Of the 38
children, two were lost to follow-up before the start of the trial, parents of 10
children decided not to participate in the trial and we excluded one child with
severe brain damage. Ultimately, 25 children were included in the trial.
Basic characteristics of participants, treatment exposure and safety endpoints
were collected for all participants. The primary objective was to investigate
whether intranasal insulin leads to a greater increase in the level of general
developmental functioning compared with the change in developmental
functioning without insulin. The secondary objective was to investigate whether
intranasal insulin leads to an improved functioning of adaptive and social-
emotional behaviour.
Treatment allocation
The study period consisted of a pre-clinical trial phase and a clinical trial phase
(Figure 1). During the pre-clinical trial phase, patients and their parents visited
our expert clinic for Rare Chromosome Disorders. A patient history was taken
and a physical examination was performed by a paediatrician (GB) to evaluate
potential health issues. Patients were randomly allocated to one of the study
groups. Randomisation was done by the Department of Clinical Pharmacy and
Pharmacology of the University Medical Centre Groningen using a restricted
randomisation method with permuted blocks of three groups (A, B and C).
During the clinical trial phase, following the pre-treatment assessment
(t= 0 months), participants started with either intranasal insulin (group A)
or intranasal placebo (group B and C) according to schedule (Figure 1). Study
investigators, parents and participants were blinded for treatment allocation.
Study medication and placebo
According to schedule, patients received a set of nose sprays with either insulin
or placebo solution each 6-month period. The recombinant human insulin
solution for this study consisted of the licensed parenteral drug Humuline
Regular 100 IU/ml (Eli Lilly Nederland B.V., Houten, The Netherlands). The
dosage was based on the pilot study of Schmidt et al. 2009.15 Our Department
of Clinical Pharmacy and Pharmacology repackaged this product in multi-dose
nasal spray bottles (Aeropump, Hochheim am Main, Germany). One spray was
0.1 ml, containing 10 IU of insulin. The composition and packaging of the
placebo solution was identical to the insulin buffer solution. In the placebo
solution, insulin was replaced by human albumin (Albuman 200 g/l, Sanquin,
Amsterdam, The Netherlands) to a concentration of 3.47 mg/ml.
In previous studies, the maximum dose that had been safely administered to
adults was 160 IU/day (~2.5 IU/kg/day)17 and to children 20–60 IU/day (0.5–
1.5 IU/kg/day).15,18 The daily dose for our study was calculated so that the
maximal safe dose from previous studies was maintained, but maximal levels in
the CSF would be achieved. Because head circumference in children corre-
sponds to their brain volume,19 we calculated the insulin dose based on both
estimated body weight20 and head circumference21 (a proxy for cranial volume)
to ﬁnd the optimal therapeutic dose (Table 1). The medication was
administered twice a day: just before breakfast and dinner. When two sprays
were scheduled, parents administered one spray to each nostril. The medication
was accompanied by administration instructions for the parents.
Safety
Several independent studies have shown that intranasal insulin administration
did not alter systemic insulin concentration or glucose levels in children and
adults.13,15,18 Therefore, peripheral glucose or insulin levels were not measured
in study participants. Safety and tolerability were evaluated based on both
expected and unexpected adverse events and SAEs as reported by parents to the
investigators by email, phone and through their participant diaries. Previously
Figure 1 Study design. Trial phases, study groups and study periods. B, baseline; I, intranasal insulin; P, intranasal placebo. t= time point (in months) at
which development and behaviour were assessed.
Table 1 Biometric characteristics and dose of study medication
Body Cranial Dose based on
Age weight a volume b Dose Weight Volume Administration
(years) (kg) litres (l) IU/day IU/kg/day IU/l/day no of spraysc
1–3 10–15 1.0–1.1 20 1.3–2.0 18.2–20.0 2 dd 1
3–9 15–30 1.1–1.25 30 1.0–2.0 24.0–27.3 1 dd 2 + 1 dd 1
9–18 30–65 1.25–1.5 40 0.6–1.3 26.7–32.0 2 dd 2
aEstimated body weight (based on ref. 18).
bEstimated cranial volume (ref. 19).
cOne nasal spray is 0.1 ml and contains 10 IU.
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reported, and therefore expected, adverse events were transitory nasal irritation,
rhinitis, spontaneous nose bleeds and headache.13 As the placebo buffer
solution consisted of the same components as the insulin buffer solution, the
potential adverse effects of the placebo solution were expected to be similar.
Outcome measures
To measure the effect of intranasal insulin, development and behavioural
functioning were assessed at 6-month time intervals by different tests (see next
section). The rates of improvement of development and behaviour in the
treatment period were then compared to the rates of improvement in the pre-
treatment period.
The results from the t=− 6 and t= 0 month assessments of the pre-clinical
trial phase were used to determine baseline changes in general development and
behaviour.
In the clinical trial phase, each subsequent treatment period consisted of
6 months at the end of which time development and behaviour were assessed
(t= 6, t= 12 and t= 18 months). Immediately after each assessment, partici-
pants switched to a new set of nose sprays (Figure 1). Once started on
intranasal insulin, participants remained on insulin until the end of the trial.
Assessment of development and behaviour
Two licensed clinical child psychologists with professional experience, inten-
sively trained in the administration of the instruments used in this study and
experienced in working with children with special needs, assessed children at
home or in their school environment. General development, our primary
outcome parameter, was assessed by the Bayley Scales of Infant and Toddler
Development,22 third edition, adapted and validated for the Dutch population
(Bayley-III-NL),23 or Wechsler Preschool and Primary Scale of Intelligence,24
third edition, Dutch version (WPPSI-III-NL)25 depending on the develop-
mental age of the children. Bayley-III-NL and WPPSI-III-NL outcomes are
expressed in raw scores that were converted to a developmental age equivalent
(DAE) as previously described.3
Behaviour, our secondary outcome parameter, was assessed by two ques-
tionnaires applied in interview form: the Vineland Screener 0–6 and the
Experimentele Schaal voor de beoordeling van het Sociaal-Emotionele Ontwikkel-
ings Niveau (ESSEON). The Vineland screener 0–6, which is based on the
American short version of the Vineland Adaptive Behavior Scales (VABS),26
was used to cover four domains of adaptive behaviour portrayed in the original
Expanded Version of the VABS: communication, social, daily and motor skills.
The Vineland Screener has been validated for Dutch children aged 0–6 years
and for children between 1 and 18 years with a developmental delay.27 Raw
scores of each subscale were converted to a DAE. The ESSEON is a Dutch
instrument that determines the level of social and emotional development of
children from 0 to 14 years of age.28 It is a behaviour rating scale based on
interviewing adults with knowledge of the child’s behaviour, resulting in a DAE
for each subscale. There is some overlap between the Vineland Screener and the
ESSEON with respect to aspects of adaptive behaviour-like social and
communicative abilities, but these questionnaires are complementary with
respect to emotional development.
In addition to our primary and secondary objectives, we evaluated
behavioural problems, which were assessed using two questionnaires: the
BRIEF-P29 and the Child Behavior Checklist (CBCL/1.5-5).30 Methods and
results are described in Supplementary File.
Statistics
The statistical analysis for treatment effect was conducted using a subject-
speciﬁc random coefﬁcients (linear mixed) model which has been described
previously (SWD-S3).16 It is based on comparing the change in DAE (with
respect to change in biological age) for each individual subject from the control
period, for example, the period of baseline and/or placebo, with the period in
which children received intranasal insulin. A P-valueo0.05 was considered to
be statistically signiﬁcant. The intention-to-treat analysis was performed with all
participants and in all periods. The on-treatment analysis was performed based
on all periods in which participants had a 490% treatment adherence, which
was evaluated by returned medication and participant diaries. A subgroup
analysis was performed for children436 months who usually show a decrease
or stagnation of developmental growth3 to see whether this has implications for
the treatment effect.
Ethical considerations and trial registration
The Institutional Medical Ethical Review Board of the University Medical
Centre Groningen approved this study (protocol ID 2012/329) and all parents
provided written informed consent. The study was conducted according to the
principles of the Declaration of Helsinki (version 59th WMA General Assembly,
Seoul, October 2008) and in accordance with the Medical Research Involving
Human Subjects law (WMO, 26 February 1998, version 1 March 2006). The
clinical trial (local protocol code number 2013.2015) was registered at the
national competent authority (NL-41213-042-12), the Netherlands Trial
Register (NTR 3758) and the EU Clinical Trial Register (2012-002873-77).
RESULTS
Subjects
Twenty-ﬁve children participated in the trial, 6 males and 19 females,
of whom 23 fully completed the treatment period (Table 2 and next
section). Clinical characteristics of these patients have been described
previously (patients 1, 2, 4, 5, 8, 9, 11–14, 16, 17, 19, 20, 22, 23 and
26–34).3 Nine children were randomised in group A, 8 in group B and
8 in group C.
Treatment adherence and Safety
In general, treatment adherence was high in this study. One child did
not receive sufﬁcient medication during periods 2 and 3 due to social
circumstances (inability to properly organise the spray application),
one child received ~2/3rds of the daily dose in period 3 on the
parents’ own initiative and one child received ~ 80% of the medication
in period 3 because the parents forgot to administer the medication
several times.
Two children did not ﬁnish the whole-treatment period of the study
due to non-SAEs. One child suffered from abdominal pain at the end
of period 2 (under placebo) and subsequent paediatric evaluation
suggested mild pancreatitis with elevated amylase levels. A relation
with the nasal spray was not likely as this child had been using this
batch of spray for at least 5 months and none of the other children
had similar complaints. Nonetheless, the parents decided to discon-
tinue with the study. Another child used the nasal sprays until the
fourth week of period 3, but had suffered from recurrent nosebleeds
beginning in period 2 so that the parents decided to discontinue the
medication for a while but then forgot to restart treatment.
No SAEs or suspected serious adverse reactions have been reported.
Expected adverse events such as nosebleeds and irritation of the nasal
area were frequently reported (12 of 25 children). These were limited
to 1 or 2 days and usually occurred only once per period in both
placebo and insulin groups. Most other adverse events reported, like
upper airway infections and gastro-enteritis, are common in children
and occurred in both placebo and insulin groups.
Table 2 Baseline characteristics of the study group at t=0
n=25 Mean (SD) Median Range
Age (months) 82.5 (47.8) 75.0 13–189
Deletion size (Mb) 3.9 (2.5) 3.4 0.18–7.8
Cognitive DAE at start (months) 18.0 (11.1) 14.0 5.1–53
Mean weight at start (kg) 25.3 (13.8) 24.0 8–60
Head circumference at start (cm) 50.8 (3.2) 50.5 44.7–56
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Primary and secondary endpoints
Table 3 shows the results of the intention-to-treat analyses on general
and behavioural development, displaying the mean changes in DAE
for the pre-treatment period (control rate), the additional increases in
DAE in the treatment period (insulin effect) and the changes in DAE
combined (total rate).
In the pre-treatment period, the mean change in DAE ranged from
0.4 to 1.8 months per 6 months for the ﬁve domains of general
development (Bayley-III-NL). Intranasal insulin resulted in an addi-
tional increase of the DAE for cognition (0.6 months per 6 months),
receptive language (0.6 months per 6 months) and ﬁne motor skills
(0.4 months per 6 months). Although this additional effect of
intranasal insulin for these domains was not signiﬁcant itself, the
total change in DAE with intranasal insulin was statistically signiﬁcant,
as illustrated by the 95% conﬁdence intervals (Table 3). The mean
contribution of intranasal insulin to the total change in DAE was 59,
38 and 47% for these respective domains. The change in DAE of
expressive language and ﬁne motor skills of the pre-treatment period
was already signiﬁcant and the additional effect of intranasal insulin
was approximately zero.
There was also a positive effect of intranasal insulin observed on all
four domains of adaptive behaviour (Vineland Screener 0-6) and on
social development (ESSEON). In the pre-treatment period, the
change in DAE ranged from 0.1 to 2.4 months per 6 months, except
for social skills of adaptive behaviour. Intranasal insulin resulted in an
additional increase of the DAE for all domains except emotional
development, including social skills of adaptive behaviour (Table 3).
This additional increase in DAE ranged from 0.6 to 1.4 months per
6 months. Although this additional effect of intranasal insulin was also
not statistically signiﬁcant itself, the total change in DAE with
intranasal insulin was signiﬁcant in contrast to the change in DAE
without insulin treatment. The mean contribution of intranasal insulin
to the total change in DAE was 480% for adaptive behaviour and
19% for social development. The on-treatment analysis did not result
in different outcomes for development or behaviour (data not shown).
The subgroup analysis of children aged 436 months is shown on
the right in Table 3. Compared with the whole-study group, a lower
change in DAE in the pre-treatment period was shown for 8 of 11
domains, and a higher additional increase in DAE with insulin for 6 of
11 domains (difference of 0.1–0.4 months per 6 months). Moreover, a
statistically signiﬁcant effect of insulin was seen in this subgroup for
the domains cognition (increase in DAE 0.8 months per 6 months,
P= 0.046) and social skills (1.5 months per 6 months, P= 0.042). The
contribution of intranasal insulin to the total change in DAE was 80%
for cognition and4100% for social skills because the control rate was
negative. Remarkably, the observed additional effect of intranasal
insulin on DAE in this subgroup was positive for the domain of
expressive language (increase in DAE 0.3 months per 6 months, 21%
contribution to the total change of DAE), an effect that was not seen
in the total study group (0.0 months per 6 months).
Supplementary material 1 shows the results of the intention-to-treat
analyses for behavioural problems for the whole group as assessed by
the BRIEF-P and the CBCL/1.5-5. None of these effects were
statistically signiﬁcant or clinically observable.
DISCUSSION
The aim of this study was to evaluate whether the previously reported
positive effect of intranasal insulin on development and behaviour in
children with PMS could be conﬁrmed in a randomized, double-blind
and placebo-controlled clinical trial. Our study shows a positive
observed effect of intranasal insulin on psychomotor and behavioural
development. However, this effect of intranasal insulin was not strong
enough to reach statistical signiﬁcance in our small group of patients,
but some statistically signiﬁcant positive effects were seen in the
subgroup of children older than 3 years of age.
Obtaining signiﬁcant results from clinical trials in a small cohort of
patients is a challenge, especially in a clinically variable disorder like
PMS, and there are a number of factors that need to be considered
that may have impacted the size of the signals we measured.
First of all, our initial power analysis assumed that children with
PMS would develop at a rate of 28% of typical development
(1.7 months per 6 months) based on data from four children with
PMS.16 However, as we recently showed in a study of 34 children,
development in PMS is not a linear process and development stagnates
after the age of 3 years.3 For most of the developmental domains that
were analysed in the present study, the developmental rate under
Table 3 Results of the intention-to-treat analysis for general and behavioural development
Control rate Insulin effect Total rate Control rate Insulin effect
All ages All ages All ages Age 436 months Age 436 months
C P-value C P-value C 95% CI C P-value C P-value
B: cognition 0.40 0.30 0.57 0.11 0.97 (0.36; 1.58) 0.19 0.64 0.75 0.046
B: receptive language 1.02 0.02 0.63 0.13 1.64 (1.04; 2.25) 0.87 0.05 0.60 0.14
B: expressive language 1.35 0.002 0.05 0.92 1.39 (0.85; 1.94) 1.09 0.02 0.29 0.54
B: ﬁne motor function 0.47 0.18 0.41 0.26 0.87 (0.38; 1.37) 0.30 0.44 0.56 0.15
B: gross motor functiona 1.82 0.01 −0.07 0.92 1.75 (1.12; 2.38) 1.82 0.004 −0.01 0.99
V: communication skillsb 0.11 0.80 0.57 0.19 0.68 (0.004; 1.35) 0.14 0.76 0.56 0.32
V: social skills −0.12 0.88 1.41 0.06 1.29 (0.11; 2.47) −0.45 0.57 1.54 0.042
V: daily skills 0.14 0.78 0.84 0.14 0.97 (0.33; 1.61) 0.04 0.94 1.10 0.07
V: motor skills 0.30 0.64 1.21 0.09 1.51 (0.62; 2.40) 0.07 0.91 1.28 0.10
E: social developmenta 2.39 0.13 0.56 0.76 2.96 (1.08; 4.83) 2.31 0.18 0.93 0.64
E: emotional developmenta 0.50 0.61 0.07 0.95 0.57 (−0.59; 1.74) 0.47 0.66 0.05 0.97
Abbreviations: B, Bayley-III-NL; V, Vineland Screener 0-6 and E=ESSEON.
aThe random coefﬁcients model was reduced to a random intercept model since the variability in the slope was estimated to be zero for ‘all ages’ and ‘age 436 months’ and
bfor ‘age 436 months’ only. All ages n=25, Age 436 months n=21. The coefﬁcient (C) is an estimate of the change in DAE in months per 6 months for the pre-treatment period (control rate)
and treatment period (insulin effect). Observed insulin effects that show a clinical increase in DAE are underlined. The P-value (P) is calculated for the difference between the DAE at the beginning
and the end of these respective periods. Po0.05 is considered statistically signiﬁcant. Signiﬁcant P-values of insulin effects are bold. The conﬁdence interval (CI) represents the distribution of the
individual coefﬁcients.
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normal circumstances was therefore slower than expected, making an
additional 15–45% treatment effect of intranasal insulin based on the
previously expected higher basal rate too optimistic, further meaning
that smaller effects of intranasal insulin on DAE are hard to detect in
this sample size. Nonetheless, we saw an effect of insulin: while the
DAE without insulin did not signiﬁcantly improve over time for most
domains, the increase of DAE with intranasal insulin treatment (total
rate, Table 3) did reach statistical signiﬁcance on all domains except
emotional development. Moreover, this additional effect of intranasal
insulin contributed 19 to 480% of the total increase in DAE. This
might suggest that intranasal insulin itself has a limited and non-
signiﬁcant effect on development, but when the effect of insulin is
added to the baseline development, it may contribute to a positive
increase in development.
Second, the children who participated in the clinical trial vary
widely in calendar age, deletion size and in their level of developmental
functioning. Theoretically, this could result in a different therapeutic
effect for subgroups. We previously found that children with PMS
younger than 3 years of age have a higher natural developmental rate
than children older than 3 years of age, who increasingly deviate from
the typical developmental rate.3 Interestingly, subgroup analyses in
children older than 36 months suggested a stronger effect of intranasal
insulin in this group and showed signiﬁcant results for the effect of
intranasal insulin for the domains of cognition and social skills
(Table 3). Thus, younger children might beneﬁt less from intranasal
insulin to reach their maximal capacity for development, whereas
older children who do not develop at their maximal capacity could
beneﬁt more. Further studies are needed to support this observation.
Unfortunately, the study group was too small for a subgroup analysis
on the effect of insulin in children with small (o250 kb) versus larger
deletions and more research is required to identify those children who
might beneﬁt most from intranasal insulin.
Third, at least 7 out of the 25 children received a dose that was too
low compared with that received by other children with the same head
circumference. We had to compromise between the maximal safe dose
from previous studies (based on total body weight) and the maximal
levels we could obtain in the CSF (based on a proxy for brain volume)
because a safety study of intranasal insulin based on brain volume was
not available. If we had determined the daily dose based on the
maximal safe CSF levels, seven children would have received a higher
dose, especially the children in the youngest age group (10–15 kg).
Another challenge with intranasal application of insulin is that we
cannot determine the exact amount of ﬂuid administered in the nasal
cavity nor the actual uptake in the CSF or the distribution and
localisation in the brain tissue itself.
Finally, even though the treatment adherence appeared to be very
high, we relied on patient diaries and returned medication, which are
less objective. Still, we think that our estimations of treatment
adherence were reasonable since administration of the nose-spray
had a relatively low burden, limited adverse reactions and parents were
highly motivated to participate in the study.
Despite our modest results, we do think that intranasal insulin
could be a therapeutic strategy in children with PMS, based on the
function of insulin in the brain. Insulin and IGF-1 function as
neurotransmitters in the brain and both bind cerebral insulin, IGF-1
and insulin/IGF-1 hybrid receptors with different afﬁnity (reviewed by
Fernandez and Torres-Alemán.).31 The insulin/IGF-1 signalling path-
way is involved in dendritic spine and synapse formation upon
activation of the PI3K-Akt-mTOR signalling pathway.32 In PMS,
dendritic spine formation and synaptic signalling are impaired because
of SHANK3 haploinsufﬁciency as shown in Shank3-deﬁcient animal
models.6,33 Excitingly, IGF-1 was shown to rescue synaptic transmis-
sion impairments of neuronal stem-cells of PMS patients by decreas-
ing the number of synapses with SHANK3 and increasing the number
of synapses with PSD-95.9 In addition, insulin has been shown to
stimulate expression of the postsynaptic scaffolding protein PSD-95 in
rat neurons.34 These studies therefore suggest that the effects of
SHANK3 haploinsufﬁciency can be compensated by insulin/IGF-1
signalling via up-regulation of PSD-95 and increasing the number of
PSD-95 containing synapses. For future studies, it would also be
interesting to investigate the (short-term) effect of intranasal insulin in
the brain by measuring event-related potentials or using functional
magnetic resonance imaging. Although these techniques have not yet
been standardized or validated for testing the effect of medication on
development and behaviour in children with developmental delay,
they would be very interesting to use in follow-up experiments.
A pilot study with daily intraperitoneal IGF-1 injections in patients
with PMS showed a beneﬁcial effect on social impairment and
restrictive behaviour.11 A phase-2 study is currently ongoing in the
USA to validate the effect of IGF-1 in patients with PMS (www.
ClinicalTrials.gov ID: NCT01970345). Interestingly, intranasally
applied IGF-1 can also be transported to the CSF/brain,35 but no
clinical trials have been conducted with intranasal IGF-1 in patients
with PMS.
In conclusion, the application of intranasal insulin is a non-invasive,
safe, easy and interesting therapeutic approach to improve intellectual
and behavioural development in children with PMS. Our preliminary
results show that it increased the level of developmental functioning,
especially in children older than 3 years, who usually show a
stagnation of development. Most results were not statistically sig-
niﬁcant in our small study group but may be considered clinically
relevant. Clinical trials in larger study populations are required to
prove the true effect of intranasal insulin on development and
behaviour, and might be able to determine which individuals would
beneﬁt most from it. In addition, future studies should focus on
improving the local side-effects by adapting the insulin formulation
and by studying the effects of intranasal insulin in the brain by using
Shank3-deﬁcient animals, a model for PMS. Still, we think that
treatment with medication in children with complex disorders like
PMS should only be part of the total and individualised treatment
plan. Therapeutic support (speech, occupational, physical and beha-
vioural therapy) with attention to individual needs are as important, if
not more important, to optimise health and wellbeing in individuals
with PMS.
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